



REVIEW ARTICLE

Topical Oxygen for Chronic Wounds: A PRO/CON Debate



Mesut Mutluoglu, MD^{a,*}, Aslican Cakkalkurt, MD^b, Gunalp Uzun, MD^c, Samil Aktas, MD^d

^aDepartment of Underwater and Hyperbaric Medicine, GATA Haydarpasa Teaching Hospital, 34668 Uskudar, Istanbul, Turkey

^bDepartment of Underwater and Hyperbaric Medicine, Ankara Numune Teaching and Research Hospital, Ankara, Turkey

^cDepartment of Underwater and Hyperbaric Medicine, GATA Faculty of Medicine, Etlik, Ankara, Turkey; and

^dDepartment of Underwater and Hyperbaric Medicine, Istanbul Faculty of Medicine, Istanbul, Turkey

KEYWORDS:

Topical oxygen;
Hyperbaric oxygen;
Reactive oxygen species;
Oxidative stress;
Wound healing

Abstract The role of oxygen in wound healing is universally accepted and does not require any further evidence; however the controversy as to whether oxygen delivery systems have the potential to improve wound healing remains to be concluded. Topical oxygen treatment (TOT) involves the delivery of 100% oxygen for a mean of 90 min, once a day at an atmospheric pressure slightly above 1 atm abs. The use of TOT gained increasing interest recently. The current manuscript will summarize the pros and cons of TOT in the view of the available literature.

© 2015 Elsevier Inc. All rights reserved.

Introduction

The use of oxygen in wound healing dates back to the early 60's when hyperbaric oxygen treatment (HBO) started to be used in clinical practice. Topical oxygen treatment (TOT) has followed this introduction toward the end of that decade.¹ Although, the introduction of both treatment modalities roughly coincided with each other, the supporting evidence, obtained either by experimental or clinical studies, did not follow a parallel course. While HBO gained increasing interest throughout the following years, TOT was not as much popular until the recent decade.

Evidence derived from studies conducted on the efficiency of HBO in the treatment of non-healing wounds has erroneously been extrapolated to TOT studies.² In 2005 the Undersea

and Hyperbaric Medicine Society (UHMS) published a position statement regarding TOT use in chronic wounds and concluded that “*topical oxygen as a therapeutic strategy in wound healing is not adequately supported by scientific data.*”³ A number of studies have been published so far. In an attempt to discuss these latest studies and to contribute to this hot topic, we decided to conduct a pro/con debate session during the VI. National Underwater and Hyperbaric Medicine Conference held in Istanbul, Turkey. The authors of this paper include the two debaters (M.M., A.C.) and the two moderators (G.U., S.A.). It should be noted that the authors did not intend to compare TOT and HBO therapy in any sense, but rather aimed to focus on the efficiency or futility of TOT in the treatment of non-healing wounds.

Pro: Topical Oxygen for Wounds is Effective

Oxygen supply for chronic non-healing wounds has recently been a focus of interest for many investigators. The

None of the authors have any conflict of interest to declare.

* Corresponding author. Tel.: +90 5055981547.

E-mail address: drmutluoglu@gmail.com

partial pressure of oxygen (pO_2) is a key factor in wound healing and the literature has consistently reported that a transcutaneous pO_2 below 40 mm Hg is strongly associated with poor wound healing.⁴ While increasing pO_2 at the wound edge improves hypoxia, it also promotes several other aspects of wound healing through the production of reactive oxygen species (ROS). Recent evidence, indeed, revealed that oxygen is not merely the primary source of energy, but also generates several ROS which may function as intracellular messengers in normal cell signal transduction and cell cycling. Mechanisms of ROS action are dose dependent and the dose is closely related with pO_2 . Hydrogen peroxide (H_2O_2), for instance, reacts as an intercellular messenger at micro-molar concentrations, causes oxidative stress at milli-molar doses and is used as a disinfectant at a 3% concentrations.⁵ Because H_2O_2 is more stable than any other ROS and may easily pass across cellular membranes, it is a key messenger in regulating intercellular mechanisms through TGF- β .⁶ At μ molar doses, H_2O_2 induces neutrophil chemotaxis, endothelial adhesion⁷ and matrix metalloproteinase-1 (MMP-1),⁸ MMP-2⁹ gene expression. Additionally it triggers epidermal growth factor (EGF) dependent signal transduction.¹⁰ H_2O_2 also induces vascular endothelial growth factor (VEGF) expression from macrophages and keratinocytes.¹¹ Several enzymes responsible for collagen synthesis such as prolyl hydroxylase and lysyl hydroxylase and oxidase are known to be oxygen and ROS dependent.^{12,13} H_2O_2 promotes collagen matrix formation by inducing collagen factor I, III and IV and TGF- β 1 mRNA.¹⁴ Finally, fibroblast/myofibroblast transformation is also oxygen and ROS dependent.¹⁵

The role of ROS in wound healing has been demonstrated in an experimental model, where perfusion was shown to be significantly impaired in the absence of ROS.¹⁶ The majority of chronic wounds are stuck in the inflammatory phase due to impaired oxidative killing, a distinct function of neutrophils that involves ROS generation by NADPH oxidase. Adequate oxygen supply provides normal NADPH oxidase function and regulates cellular motility, angiogenesis and extracellular matrix formation.¹⁷

While pO_2 level and systemic factors are essential in wound perfusion, local factors are as just significant. Accordingly, increasing arterial pO_2 levels may not necessarily improve wound oxygenation. Factors such as critical ischemia, inadequate intravascular volume, disrupted vasculature, diffusion barriers, smoking and anxiety may impair wound oxygenation despite elevated arterial pO_2 levels. TOT, in this regard, may be an efficient alternate to systemic oxygen treatment modalities.

TOT may be applied in several ways. Conventional TOT involves the delivery of 100% oxygen for a mean of 90 min, once a day at an atmospheric pressure slightly above 1 atm abs.⁵ A recently developed technique differs from the conventional one in that it provides continuous oxygenation for 24–72 h.¹⁸ In this modality, an electrochemical oxygen concentrator refines and delivers atmospheric oxygen to the wound site through a cannula at 98%–100% rate.

The diffusion capacity of oxygen is poor; therefore, one may raise concerns regarding TOT and the diffusion distance. Debridement of all devitalized necrotic tissues prior to TOT application accompanied by a high gradient occurring between the source of oxygen and the wound base, however, is theorized to offset this limitation. Even if TOT had provided only a slight increase in pO_2 at the tissue level, as Piandatosi noted in his editorial in 2003, this alone would have beneficial effects on wound healing.⁴ After almost a decade from this editorial, which raised substantial concerns on the use of TOT, we now finally have supporting evidence both from experimental and clinical studies. In the following section we will initially present evidence from basic science studies supporting the physiological background of TOT and thereafter will report results from recent clinical studies confirming these findings.

Recent experimental studies have, indeed, provided concrete positive evidence on the use of TOT in wound healing. Using the Seldinger method which relies on inserting a prob (OxyLite, Oxford Optronix, Oxford, England) within 2 mm of the wound center,¹⁹ pO_2 levels were shown to rise from 5 to 7 mm Hg to above 40 mm Hg following the use of TOT in an ischemic wound model created on the back of a pig. After 6 days of daily 3 h of TOT, the size of the wounds in the TOT group were found to be significantly smaller, VEGF protein expression higher and revascularization more significant than the control wounds. Furthermore, a repeat assessment of pO_2 levels at day 22 revealed a persistent increase of pO_2 (42 mm Hg) on wounds treated with TOT as opposed to control wounds (11 mm Hg). In an ischemic rabbit ear model, the effects of continuous TOT were assessed on 7 mm circular wounds.²⁰ Following 8 days of treatment, wounds in the TOT group had significantly more epithelialization on histologic examination as compared with control wounds. Additionally, activator protein-1 (AP-1) levels, a marker for keratinocyte transcription, assessed on PCR were significantly higher in rabbits in the TOT group.

Clinical studies have confirmed the evidence obtained from experimental studies. A large number of observational studies reported successful results with TOT.^{21–24} In a recent observational case series study, Gordillo et al, reported promising results with TOT in patients with non-healing chronic wounds who achieved good wound healing, an observation which was confirmed by a significant increase in VEGF expression on biopsy samples obtained from the edge of the wounds.²⁵ In a more recent non-randomized controlled study conducted by Blackman et al on 28 patients with diabetic foot ulcers (DFUs), the mean healing duration was shown to be significantly shorter with TOT as compared with standard wound care [56 days in 14 of the 17 (82.4%) patients vs. 93 days in 5 of the 11 patients (45.5%)].²⁶ Finally, Vickie et al, in a randomized controlled trial performed on patients with chronic DFUs, confirmed these findings by demonstrating that patients who received continuous TOT for 4 weeks had significantly higher wound size reduction as compared with patients who received standard wound

care alone [87% (range 55.7%–100%) vs 46% (15%–99%); $p < 0.05$].²⁷ The difference in the change in cytokine (IL-6, IL-8) and proteinase (MMP-1,-2,-9, TIMP-1) levels between the groups strengthened these results ($p < 0.01$). TOT opponents frequently cite a randomized controlled study conducted by Leslie et al as a clear evidence that TOT is not effective.²⁸ This study, however, has serious methodological flaws. The most significant of these is that, although TOT does not penetrate to bone, a substantial rate of patients with findings suggestive of osteomyelitis were included in the study [6 (50%) of the patients receiving TOT had abnormal bone scans or x rays and above 70 mm/h sedimentation rate].

In conclusion, current experimental and clinical evidence support the rationale behind the use of TOT in wound healing.

Con: Topical Oxygen for Wounds is Not Effective

Oxygen plays a central role in wound healing. While, at the early stage of wound healing, low (hypoxia) pO_2 is an essential stimulator of growth factors, cytokines, gene activation and angiogenesis,²⁹ normal (normoxia) or increased (hyperoxia) levels of pO_2 are more favorable during the subsequent stages of wound healing.³⁰ Fibroblast and endothelial cell proliferation, for instance, occurs best at a pO_2 of 30–80 mm Hg and collagen synthesis, neovascularization and epithelialization all require a pO_2 between 20 and 60 mm Hg.³¹ Actually, the role of oxygen in wound healing is universally accepted and does not require any further evidence.³² The controversy, however, as to which oxygen delivery systems have the potential to restore or increase the rate of oxygen within the wound milieu remains to be concluded.

The literature, hence the evidence, about the use of TOT in chronic wounds is limited and to describe the mechanism of action of TOT, the majority of these reports refer to the evidence obtained from studies related to HBO, which apart from using oxygen does not have much in common. Proponents of TOT claim that it may efficiently deliver oxygen within the wound layers, an assumption which has not gained wide acceptance due to limited evidence. Piantodasi demonstrated that topical oxygen could diffuse through a maximum distance of 50–100 microns and hence claimed that the amount of oxygen absorbed through open wounds would be extremely small.³³ Moreover, given the debris, biofilm layers and devitalized tissues over the wound surface, it would be much assertive to pretend that topical oxygen would efficiently diffuse through all these barriers.

TOT has, let alone its efficacy, several significant pitfalls. First, an increase in the regional pressure of the affected limb may impede circulation, and thereby impair

wound healing.³⁴ Moreover, limb ischemia may occur in case this pressure exceeds the arterial systolic pressure, or vascular congestion if it exceeds arterial diastolic pressure.⁴ Second, several experiments demonstrated that a hypoxic tissue gradient, i.e., from the periphery to the center of the wound, is mandatory for angiogenesis and that when this hypoxic gradient is destroyed capillary growth ceases.²⁹ Therefore, even if TOT had increased wound pO_2 levels, it would do this at the center of the wound and would reverse this gradient, eventually resulting in the inhibition of angiogenesis.³⁴

Transcutaneous partial oxygen pressure ($TcPO_2$) levels, which has seldom been assessed in TOT studies, were reported not to significantly increase in two studies conducted by Cotto-Cumbo³⁵ and Mostellar.³⁶ Mostellar et al,³⁶ using 6 healthy subjects, compared the influence of HBO and TOT on $TcPO_2$ levels and demonstrated 49% decrease with TOT and 1309% increase with HBOT. Heng et al reported negative influence of TOT on collagen synthesis and fibroblast proliferation.^{37,38} Heng et al reproduced these findings in a prospective controlled study where 13 patients treated with TOT displayed decreased collagen synthesis and fibroblast proliferation.³⁹ Leslie et al, in a randomized controlled study showed that patients receiving TOT ($n = 12$) displayed a longer healing duration as opposed to patients who received standard care alone ($n = 16$).²⁸ In this study TOT was administered to patients with DFUs in two daily 90-min sessions through a leg chamber that provided humidified 100% oxygen at pressures cycled between 0 and 30 mm Hg (i.e., up to 1.04 atm abs) every 20 s. At day 14 wound size was significantly reduced in all patients, irrespective of which group they were assigned to ($p > 0, 05$). Finally, although fibroblast proliferation and collagen production are widely appreciated as strong indicators of wound healing, several studies, interestingly, have claimed their reduction as a benefit of TOT.^{37–39}

To conclude, given the physical properties of oxygen, its limited diffusion distance and poor clinical results obtained from the above mentioned studies, TOT may not currently be recommended for routine use on wounds.

Conclusion

The pros and cons of TOT are summarized in [Table 1](#). TOT may have a role in wound management and deserves further research however given the fact that TOT does not penetrate to bone and hence would not be efficient for Wagner 3 and higher grade wounds, and that the majority of Wagner grade 1 and 2 wounds already have a big chance of healing with standard measures alone, the use of TOT should currently be restricted to the wounds that fail to show a tendency toward healing for at least 2–4 weeks of treatment with standard wound care. In view of the current

Table 1 Advantages and Disadvantages of Topical Oxygen.**Advantages**

- Lower cost as opposed to HBO
- Home treatment option
- No complications such as middle-ear barotrauma as observed in HBOT
- No risk of systemic oxygen toxicity
- No risk of claustrophobia
- Ability to penetrate the wound directly from the surface and not from disrupted vasculature

Disadvantages

- May cause ischemia in case the pressure within the closed medium exceeds systolic pressure
- May cause vascular congestion in case the pressure within the closed medium exceeds diastolic pressure
- May not allow concurrent negative pressure wound treatment
- Does not penetrate to bone
- May cause cell toxicity

poor volume and quality of scientific evidence supporting its use, TOT application should not be recommended outside of a clinical trial. We do not recommend third party pay or reimbursement. Before its routine use, TOT application should be subjected to the same intense scientific scrutiny to which systemic hyperbaric oxygen has been.

References

1. Fisher BH: Topical hyperbaric oxygen treatment of pressure sores and skin ulcers. *Lancet*. 1969;2(7617):405–409.
2. Orsted HL, Randy P, Joseph B, et al: Evidence-based practice standards for the use of topical pressurised oxygen therapy. *Int Wound J*. 2012;9:271–284.
3. Feldmeier JJ, Hopf HW, Warriner RA 3rd, Fife CE, Gesell LB, Bennett M: UHMS position statement: topical oxygen for chronic wounds. *Undersea Hyperb Med*. 2005 May-Jun;32(3):157–168.
4. Piantadosi CA: Topical oxygen is not hyperbaric oxygen (HBO2). *Undersea Hyperb Med*. 2003 Winter;30(4):267–269.
5. Sen CK, Khanna S, Gordillo G, Bagchi D, Bagchi M, Roy S: Oxygen, oxidants, and antioxidants in wound healing: an emerging paradigm. *Ann N Y Acad Sci*. 2002;957:239–249.
6. Junn E, Lee KN, Ju HR, et al: Requirement of hydrogen peroxide generation in TGF-beta 1 signal transduction in human lung fibroblast cells: involvement of hydrogen peroxide and Ca²⁺ in TGF-beta 1-induced IL-6 expression. *J Immunol*. 2000;165:2190–2197.
7. Fraticelli A, Serrano CV Jr., Bochner BS, Capogrossi MC, Zweier JL: Hydrogen peroxide and superoxide modulate leukocyte adhesion molecule expression and leukocyte endothelial adhesion. *Biochim Biophys Acta*. 1996;1310:251–259.
8. Wenk J, Brenneisen P, Wlaschek M, et al: Stable overexpression of manganese superoxide dismutase in mitochondria identifies hydrogen peroxide as a major oxidant in the AP-1-mediated induction of matrix-degrading metalloproteinase-1. *J Biol Chem*. 1999;274:25869–25876.
9. Yoon SO, Park SJ, Yoon SY, Yun CH, Chung AS: Sustained production of H₂O₂ activates pro-matrix metalloproteinase-2 through receptor tyrosine kinases/phosphatidylinositol 3-kinase/NF-kappa B pathway. *J Biol Chem*. 2002;277:30271–30282.
10. Goldkorn T, Balaban N, Matsukuma K, et al: EGF-Receptor phosphorylation and signaling are targeted by H₂O₂ redox stress. *Am J Respir Cell Mol Biol*. 1998;19:786–798.
11. Cho M, Hunt TK, Hussain MZ: Hydrogen peroxide stimulates macrophage vascular endothelial growth factor release. *Am J Physiol Heart Circ Physiol*. 2001;280:H2357–H2363.
12. Prockop D, Kivirikko K, Tuderman L, Guzman N: The biosynthesis of collagen and its disorders (part 1). *N Engl J Med*. 1979;301:13–23.
13. Prockop D, Kivirikko K, Tuderman L, Guzman N: The biosynthesis of collagen and its disorder (part 2). *N Engl J Med*. 1979;301:77–85.
14. Nath KA, Grande J, Croatt A, Haugen J, Kim Y, Rosenberg ME: Redox regulation of renal DNA synthesis, transforming growth factor-beta1 and collagen gene expression. *Kidney Int*. 1998;53:367–381.
15. Roy S, Khanna S, Bickerstaff A, et al: Oxygen sensing by primary cardiac fibroblasts. A key role of p21Waf1/Cip1/Sdi1. *Circ Res*. 2003;92:264–271.
16. KHODR B, KHALIL Z: Modulation of inflammation by reactive oxygen species: implications for aging and tissue repair. *Free Radic Biol Med*. 2001;30:1–8.
17. Gordillo GM, Sen CK: Revisiting the essential role of oxygen in wound healing. *Am J Surg*. 2003 Sep;186(3):259–263.
18. Lowell D, Johnson F, Lyons MC: Transdermal continuous oxygen therapy as an adjunct for treatment of recalcitrant and painful wounds. *Foot Ankle Online J*. 2009;2(9):4.
19. Ahn ST, Mustoe TA: Effects of ischemia on ulcer wound healing: a new model in the rabbit ear. *Ann Plast Surg*. 1990;24:17–23.
20. Rayner TE, Yates S: Transcription factor activation in response to cutaneous injury: role of AP-1 in reepithelialization. *Wound Repair Regen*. 2002;10:5–15.
21. Fischer BH: Treatment of ulcers on the legs with hyperbaric oxygen. *J Dermatol Surg*. 1975;1:55–58.
22. Diamond E, Forst MB, Hyman SA, et al: The effect of hyperbaric oxygen on lower extremity ulcerations. *J Am Podiatry Assoc*. 1982;72:180–185.
23. Heng MCY, Pilgrim JP, Beck FWJ: A simplified hyperbaric oxygen technique for leg ulcers. *Arch Dermatol*. 1984;120:640–645.
24. Heng MCY, Harker J, Bardakjian VB, et al: Enhanced healing and cost effectiveness of low pressure oxygen therapy in healing necrotic wounds: a feasibility study of technology transfer. *Ostomy Wound Manage*. 2000;46:52–62.
25. Gordillo GM, Roy S, Khanna S, et al: Topical oxygen therapy induces vascular endothelial growth factor expression and improves closure of clinically presented chronic wounds. *Clin Exp Pharmacol Physiol*. 2008;35:957–964.
26. Blackman E, Moore C, Hyatt J, Railton R, Frye C: Topical wound oxygen therapy in the treatment of severe diabetic foot ulcers: a prospective controlled study. *Ostomy Wound Manage*. 2010 Jun;56(6):24–31.
27. Driver VR, Kantarci A, Gu G, Hasturk H: A prospective, randomized clinical study evaluating the effect of transdermal continuous oxygen therapy on biological processes and foot ulcer healing in persons with diabetes mellitus. *Ostomy Wound Manage*. 2013;59(11):19–26.
28. Leslie CA, Sapico FL, Ginunas VJ, Adkins RH: Randomized controlled trial of topical hyperbaric oxygen for treatment of diabetic foot ulcers. *Diabetes Care*. 1988 Feb;11(2):111–115.
29. Knighton DR, Silver IA, Hunt TK: Regulation of wound-healing angiogenesis: effect of oxygen gradients and inspired oxygen concentration. *Surgery*. 1981;90:262–270.
30. Silver IA: The measurement of oxygen tension in healing tissue. *Prog Respir Res*. 1969;3:124–135.
31. Niinikoski J, Hunt TK, Dunphy JE: Oxygen supply in healing tissue. *Am J Surg*. 1972;123:247–252.
32. Hunt TK, Niinikoski J, Zederfeldt B: Role of oxygen in repair processes. *Acta Chir Scand*. 1972;138:109–110.
33. Piantadosi CA: Physiology of hyperbaric hyperoxia. *Respir Care Clin N Am*. 1999;5(1):7–19.

34. Cronjé FJ: Oxygen therapy and wound healing – topical oxygen is not hyperbaric oxygen therapy. *S Afr Med J*. November 2005; 95(11).
35. Cotto-Cumbo C, Velez E, Velu SS, Britten J, Myers RAM: Transcutaneous oxygen measurements in normal subjects using topical HBO control module. In: Undersea and Hyperbaric Medical Society Annual Scientific Meeting; 1991.
36. Mostellar JA, Sembrat MM, McGarvey ST, Quinn JL, Klausner EG, Sloat GB: A Comparison of Transcutaneous Oxygen Pressures between Hyperbaric Oxygen and Topical Oxygen. Undersea and Hyperbaric Medical Society, Inc; 1999.
37. Heng MCY, Harker J, Csathy G, et al: Angiogenesis in necrotic ulcers treated with hyperbaric oxygen. *Ostomy Wound Manage*. 2002;46:18–32.
38. Heng MCY: Topical hyperbaric oxygen for problem skin wounds. *J Dermatol Surg Oncol*. 1993;19:784–793.
39. Heng MC, Harker J, Csathy G, et al: Angiogenesis in necrotic ulcers treated with hyperbaric oxygen. *Ostomy Wound Manage*. 2000;46: 18–28. 30–32.